Benjamin D Simpson, P.A. Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 3567 W. Mt. Whitney Ave., Riverdale, CA 93656 Phone: 559-867-4416 Fax: 559-867-3010 |
Yonas Worku, Physician Assistant Medicare: Medicare Enrolled Practice Location: 3567 Mt. Whitney Avenue, Riverdale, CA 93656 Phone: 559-867-7200 |
Stanton Herrick Brown, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3567 Mt. Whitney, Riverdale, CA 93656 Phone: 559-867-7200 Fax: 559-867-0152 |
News Archive
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.
Scientists are making strides toward unraveling the surprisingly complex chemistry underpinning that axiom of infant feeding "breast is best," according to an article in the current edition of Chemical & Engineering News.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say.
› Verified 9 days ago